<p>Celldex Therapeutics（纳斯达克股票代码：CLDX - 获取免费报告）在周三发布的一份报告中，巴克莱的股票研究分析师将其目标价从 21.00 美元上调至 24.00 美元，Benzinga 报道。该券商目前对这家生物制药公司的股票给予 “减持” 评级。巴克莱的目标价意味着该公司股价可能下跌 9.62%。</p>
<p>获取 <strong>Celldex Therapeutics</strong> 的提醒：</p>
<p>其他一些分析师最近也对该股票发表了评论。Canaccord Genuity Group 在 9 月 17 日的报告中重申了对 Celldex Therapeutics 的 “买入” 评级，并给出了 62.00 美元的目标价。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Celldex Therapeutics 的 “卖出（d-）” 评级。HC Wainwright 在 8 月 20 日的报告中将 Celldex Therapeutics 的目标价从 50.00 美元下调至 42.00 美元，并给予该公司 “买入” 评级。瑞穗证券在 10 月 21 日的研究报告中开始覆盖 Celldex Therapeutics 的股票，给予 “跑赢大盘” 评级和 48.00 美元的目标价。最后，花旗集团在 8 月 20 日的报告中将 Celldex Therapeutics 的目标价从 56.00 美元下调至 48.00 美元，并给予该公司 “买入” 评级。一位股票研究分析师对该股票给予了强烈买入评级，七位给予买入评级，一位给予持有评级，两位给予卖出评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “适度买入”，共识目标价为 44.10 美元。</p>
<p><strong>查看我们对 Celldex Therapeutics 的最新股票分析</strong></p>
<h2>Celldex Therapeutics 股价下跌 0.5%</h2>
<p>纳斯达克 CLDX 在周三下跌 0.13 美元，报 26.56 美元。该股票交易量为 190,756 股，而其平均交易量为 993,017 股。该公司的市值为 17.6 亿美元，市盈率为-7.86，贝塔值为 1.13。该股票的 50 日移动平均线为 26.38 美元，200 日移动平均线为 24.00 美元。Celldex Therapeutics 的 12 个月低点为 14.40 美元，12 个月高点为 30.50 美元。</p>
<p>Celldex Therapeutics（纳斯达克股票代码：CLDX - 获取免费报告）最后一次公布季度财报是在 11 月 10 日，生物制药公司报告每股收益（EPS）为-1.01 美元，低于市场共识预期的-0.88 美元，差距为 0.13 美元。Celldex Therapeutics 的股本回报率为-33.22%，净利润率为-3,446.88%。整体来看，股票研究分析师预计 Celldex Therapeutics 在本年度的每股收益将为-2.48 美元。</p>
<h2>Celldex Therapeutics 的内部活动</h2>
<p>在相关消息中，内部人士 Richard M. Wright 于 11 月 13 日星期四出售了 49,298 股该公司的股票。股票以平均价格 24.00 美元出售，总交易额为 1,183,152.00 美元。交易后，该内部人士直接持有该公司 20,833 股，价值约 499,992 美元。此次交易使其持股比例减少了 70.29%。该交易已在向证券交易委员会提交的文件中披露，您可以通过此链接访问。公司内部人士目前持有 4.40% 的股份。</p>
<h2>机构资金流入和流出</h2>
<p>机构投资者和对冲基金最近调整了对该股票的持有。Aster Capital Management DIFC Ltd 在第三季度购买了 Celldex Therapeutics 的新股份，价值约 26,000 美元。Nisa Investment Advisors LLC 在第二季度将其在 Celldex Therapeutics 的股份增加了 171.7%。Nisa Investment Advisors LLC 目前持有 1,394 股该生物制药公司的股票，价值 28,000 美元，此前在上个季度增持了 881 股。Wilmington Savings Fund Society FSB 在第三季度购买了 Celldex Therapeutics 的新股份，价值 42,000 美元。Russell Investments Group Ltd.在第二季度将其在 Celldex Therapeutics 的持股增加了 27.6%。Russell Investments Group Ltd.目前持有 2,315 股该生物制药公司的股票，价值 47,000 美元，此前在上个季度增持了 501 股。最后，Quantbot Technologies LP 在第三季度购买了 Celldex Therapeutics 的新头寸，价值约 63,000 美元。</p>
<h2>Celldex Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Celldex Therapeutics, Inc 是一家生物制药公司，专注于开发用于治疗各种疾病的单克隆抗体和双特异性抗体。其药物候选者包括用于治疗炎症、过敏、自身免疫及其他严重疾病的抗体基础治疗。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好五只股票，胜过 Celldex Therapeutics</li>
<li>资产配置：成功投资组合的关键。您关注自己的投资组合吗？</li>
<li>英特尔以低价收购人工智能技术</li>
<li>现在购买的三只最佳蓝筹股</li>
<li>随着下一次计算革命的展开，值得关注的四只量子股票</li>
<li>安静期到期的解释</li>
<li>工业领域的大规模突破：现在必须关注的三只股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0xEWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0xEWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元在 Celldex Therapeutics 吗？</h2>
<p>在您考虑 Celldex Therapeutics 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买，而 Celldex Therapeutics 并不在名单上。</p>
<p>虽然塞德斯医疗目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

塞德斯医疗

<p>巴克莱将 Celldex Therapeutics（NASDAQ:CLDX）的目标价从 21.00 美元上调至 24.00 美元，维持 “减持” 评级。新的目标价暗示与前一交易日收盘价相比有 9.62% 的潜在下行空间。其他分析师的评级不一，普遍评级为 “适度买入”，目标价为 44.10 美元。Celldex 最近报告了季度亏损，内部人士 Richard M. Wright 出售了股份。机构投资者已调整了对该公司的持股</p>

<p>Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) had its price target boosted by equities research analysts at Barclays from $21.00 to $24.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has an &#34;underweight&#34; rating on the biopharmaceutical company's stock. Barclays's price target points to a potential downside of 9.62% from the company's previous close.</p>
<div class="lb-trans"><p>Celldex Therapeutics（纳斯达克股票代码：CLDX - 获取免费报告）在周三发布的一份报告中，巴克莱的股票研究分析师将其目标价从 21.00 美元上调至 24.00 美元，Benzinga 报道。该券商目前对这家生物制药公司的股票给予 “减持” 评级。巴克莱的目标价意味着该公司股价可能下跌 9.62%。</p>
</div><p>Get <strong>Celldex Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Celldex Therapeutics</strong> 的提醒：</p>
</div><p>A number of other analysts also recently commented on the stock. Canaccord Genuity Group reiterated a &#34;buy&#34; rating and issued a $62.00 target price on shares of Celldex Therapeutics in a report on Wednesday, September 17th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Celldex Therapeutics in a research report on Wednesday, October 8th. HC Wainwright lowered their price target on shares of Celldex Therapeutics from $50.00 to $42.00 and set a &#34;buy&#34; rating for the company in a report on Wednesday, August 20th. Mizuho began coverage on shares of Celldex Therapeutics in a research report on Tuesday, October 21st. They set an &#34;outperform&#34; rating and a $48.00 target price for the company. Finally, Citigroup reduced their target price on shares of Celldex Therapeutics from $56.00 to $48.00 and set a &#34;buy&#34; rating for the company in a report on Wednesday, August 20th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $44.10.</p>
<div class="lb-trans"><p>其他一些分析师最近也对该股票发表了评论。Canaccord Genuity Group 在 9 月 17 日的报告中重申了对 Celldex Therapeutics 的 “买入” 评级，并给出了 62.00 美元的目标价。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Celldex Therapeutics 的 “卖出（d-）” 评级。HC Wainwright 在 8 月 20 日的报告中将 Celldex Therapeutics 的目标价从 50.00 美元下调至 42.00 美元，并给予该公司 “买入” 评级。瑞穗证券在 10 月 21 日的研究报告中开始覆盖 Celldex Therapeutics 的股票，给予 “跑赢大盘” 评级和 48.00 美元的目标价。最后，花旗集团在 8 月 20 日的报告中将 Celldex Therapeutics 的目标价从 56.00 美元下调至 48.00 美元，并给予该公司 “买入” 评级。一位股票研究分析师对该股票给予了强烈买入评级，七位给予买入评级，一位给予持有评级，两位给予卖出评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “适度买入”，共识目标价为 44.10 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on Celldex Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Celldex Therapeutics 的最新股票分析</strong></p>
</div><h2>Celldex Therapeutics Trading Down 0.5%</h2>
<div class="lb-trans"><h2>Celldex Therapeutics 股价下跌 0.5%</h2>
</div><p>NASDAQ CLDX traded down $0.13 on Wednesday, hitting $26.56. 190,756 shares of the stock traded hands, compared to its average volume of 993,017. The company has a market capitalization of $1.76 billion, a P/E ratio of -7.86 and a beta of 1.13. The stock has a 50-day moving average of $26.38 and a 200 day moving average of $24.00. Celldex Therapeutics has a twelve month low of $14.40 and a twelve month high of $30.50.</p>
<div class="lb-trans"><p>纳斯达克 CLDX 在周三下跌 0.13 美元，报 26.56 美元。该股票交易量为 190,756 股，而其平均交易量为 993,017 股。该公司的市值为 17.6 亿美元，市盈率为-7.86，贝塔值为 1.13。该股票的 50 日移动平均线为 26.38 美元，200 日移动平均线为 24.00 美元。Celldex Therapeutics 的 12 个月低点为 14.40 美元，12 个月高点为 30.50 美元。</p>
</div><p>Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last announced its quarterly earnings results on Monday, November 10th. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.13). Celldex Therapeutics had a negative return on equity of 33.22% and a negative net margin of 3,446.88%. As a group, equities research analysts expect that Celldex Therapeutics will post -2.48 earnings per share for the current year.</p>
<div class="lb-trans"><p>Celldex Therapeutics（纳斯达克股票代码：CLDX - 获取免费报告）最后一次公布季度财报是在 11 月 10 日，生物制药公司报告每股收益（EPS）为-1.01 美元，低于市场共识预期的-0.88 美元，差距为 0.13 美元。Celldex Therapeutics 的股本回报率为-33.22%，净利润率为-3,446.88%。整体来看，股票研究分析师预计 Celldex Therapeutics 在本年度的每股收益将为-2.48 美元。</p>
</div><h2>Insider Activity at Celldex Therapeutics</h2>
<div class="lb-trans"><h2>Celldex Therapeutics 的内部活动</h2>
</div><p>In related news, insider Richard M. Wright sold 49,298 shares of the business's stock in a transaction dated Thursday, November 13th. The shares were sold at an average price of $24.00, for a total transaction of $1,183,152.00. Following the transaction, the insider directly owned 20,833 shares in the company, valued at approximately $499,992. The trade was a 70.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this link. 4.40% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在相关消息中，内部人士 Richard M. Wright 于 11 月 13 日星期四出售了 49,298 股该公司的股票。股票以平均价格 24.00 美元出售，总交易额为 1,183,152.00 美元。交易后，该内部人士直接持有该公司 20,833 股，价值约 499,992 美元。此次交易使其持股比例减少了 70.29%。该交易已在向证券交易委员会提交的文件中披露，您可以通过此链接访问。公司内部人士目前持有 4.40% 的股份。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Institutional investors and hedge funds have recently modified their holdings of the stock. Aster Capital Management DIFC Ltd bought a new stake in shares of Celldex Therapeutics in the third quarter worth about $26,000. Nisa Investment Advisors LLC boosted its stake in Celldex Therapeutics by 171.7% during the second quarter. Nisa Investment Advisors LLC now owns 1,394 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 881 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in shares of Celldex Therapeutics in the third quarter worth $42,000. Russell Investments Group Ltd. raised its holdings in Celldex Therapeutics by 27.6% in the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company's stock worth $47,000 after buying an additional 501 shares during the last quarter. Finally, Quantbot Technologies LP bought a new position in Celldex Therapeutics during the third quarter valued at approximately $63,000.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近调整了对该股票的持有。Aster Capital Management DIFC Ltd 在第三季度购买了 Celldex Therapeutics 的新股份，价值约 26,000 美元。Nisa Investment Advisors LLC 在第二季度将其在 Celldex Therapeutics 的股份增加了 171.7%。Nisa Investment Advisors LLC 目前持有 1,394 股该生物制药公司的股票，价值 28,000 美元，此前在上个季度增持了 881 股。Wilmington Savings Fund Society FSB 在第三季度购买了 Celldex Therapeutics 的新股份，价值 42,000 美元。Russell Investments Group Ltd.在第二季度将其在 Celldex Therapeutics 的持股增加了 27.6%。Russell Investments Group Ltd.目前持有 2,315 股该生物制药公司的股票，价值 47,000 美元，此前在上个季度增持了 501 股。最后，Quantbot Technologies LP 在第三季度购买了 Celldex Therapeutics 的新头寸，价值约 63,000 美元。</p>
</div><h2>Celldex Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Celldex Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.</p>
<div class="lb-trans"><p>Celldex Therapeutics, Inc 是一家生物制药公司，专注于开发用于治疗各种疾病的单克隆抗体和双特异性抗体。其药物候选者包括用于治疗炎症、过敏、自身免疫及其他严重疾病的抗体基础治疗。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Celldex Therapeutics</li>
<li>Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?</li>
<li>Intel Snaps Up AI Tech for Pennies on the Dollar</li>
<li>The 3 Best Blue-Chip Stocks to Buy Now</li>
<li>4 Quantum Stocks to Watch as the Next Computing Revolution Unfolds</li>
<li>Quiet Period Expirations Explained</li>
<li>Massive Breakout in Industrials: 3 Must-Watch Stocks Now</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好五只股票，胜过 Celldex Therapeutics</li>
<li>资产配置：成功投资组合的关键。您关注自己的投资组合吗？</li>
<li>英特尔以低价收购人工智能技术</li>
<li>现在购买的三只最佳蓝筹股</li>
<li>随着下一次计算革命的展开，值得关注的四只量子股票</li>
<li>安静期到期的解释</li>
<li>工业领域的大规模突破：现在必须关注的三只股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0xEWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=CLDX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Celldex Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元在 Celldex Therapeutics 吗？</h2>
</div><p>Before you consider Celldex Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Celldex Therapeutics 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celldex Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买，而 Celldex Therapeutics 并不在名单上。</p>
</div><p>While Celldex Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然塞德斯医疗目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

巴克莱将塞德斯医疗（NASDAQ:CLDX）的目标股价上调至 24.00 美元